Recent Finacing
Recent Raise
Avaxia Biologics develops minimally absorbed, orally delivered antibody therapeutics that act locally in the gastrointestinal tract, advancing an oral anti‑TNF for inflammatory bowel disease and other GI indications.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors